Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerHeikki Joensuu, Jorma Isola, Seija Ingalsuo et al.|New England Journal of Medicine|2006Cited by 1.4k
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer TrialHeikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono et al.|Journal of Clinical Oncology|2009Cited by 459
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancerMinna Tanner, Jorma Isola|Molecular Cancer Therapeutics|2004Cited by 269
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivoMárk Barok, Jorma Isola|Breast Cancer Research|2011Cited by 232
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort studyHarri Sihto, Heikki Joensuu, Johan Lundin et al.|Breast Cancer Research|2011Cited by 228